Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, ...

Durvalumab is currently approved for a number of cancer types. Though not approved in gastric cancer, the MATTERHORN regimen ...

HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial ...

Medication reconciliation is an important part of maintaining medication safety, and the Association of periOperative Registered Nurses calls on all perioperative RNs to focus on safety during the six ...

Researchers explained that treatment omission or discontinuation in the adjuvant setting was primarily due to postoperative complications and toxicity “but also to patient-related factors, ...

IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...

Patients with T3-4aN + M0 G/GEJ adenocarcinoma were randomly assigned (1:1:1) to receive perioperative treatment with SOXRC, SOXR, or SOX. The primary end points were pathologic complete response (pCR ...

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) IMFINZI in combination with ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...